# A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

> **NCT04412707** · PHASE2 · TERMINATED · sponsor: **Oncopeptides AB** · enrollment: 27 (actual)

## Conditions studied

- RRMM

## Interventions

- **DRUG:** Melphalan
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04412707
- **Lead sponsor:** Oncopeptides AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-04
- **Primary completion:** 2021-06-02
- **Final completion:** 2022-01-10
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04412707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04412707, "A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04412707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*